• 2009

Company Description

Delenex Therapeutics is engaged in developing therapeutic antibody fragments for diseases with high unmet needs.

Delenex Therapeutics AG is a Swiss biotech company developing therapeutic antibody fragments targeting serious medical diseases with high unmet need. The company's fragments are being designed for local/topical application by using the benefits of an antibody therapy with only limited systemic exposure. Its clinically validated technology delivers antibodies exhibiting the highest affinity, solubility and stability all combined with a very low risk of immunogenicity.

  • Manufacturer:

    Science and Engineering
  • Formed:

    2009
  • Company Website:

  • Company E-mail:

  • Company Address:

    Wagistrasse 27
    Zürich
    Switzerland
  • CEO:

    • Eric de la Fortelle
  • We recognize our sponsors starting at $1 per entry.
    Learn more at https://www.ithistory.org/benefits